报价延迟最少15分钟:2025/12/26 18:15 EST
盘后时段
|
||||
|
1.7219 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.78
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.41/--
|
|
企业价值
22.48M
|
| 资产负债 |
|
每股账面净值
0.65
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA. |
